Posted by Michael Wonder on 20 Jul 2022
FDA approves Qsymia for the treatment of obesity in adolescents ages 12-17
20 July 2022 - Vivus today announced that the U.S. FDA approved Qsymia (phentermine and topiramate extended-release capsules) for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index in the 95th percentile or greater standardised for age and sex.
According to the CDC, approximately 22% of children aged 12-19 years in the United States — about 14 million individuals — have obesity.
